To Örebro University

oru.seÖrebro universitets publikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Paroxetine concentrations in obsessive-compulsive disorder: Support for a therapeutic interval
Örebro universitet, Institutionen för medicinska vetenskaper.ORCID-id: 0000-0001-6726-7787
Department of clinical chemistry, Division of laboratory medicine, University health care in Region Skåne, Lund, Sweden.
2017 (engelsk)Inngår i: European psychiatry, ISSN 0924-9338, E-ISSN 1778-3585, Vol. 41, nr Suppl., s. S322-S322Artikkel i tidsskrift, Meeting abstract (Annet vitenskapelig) Published
Abstract [en]

Introduction: Previous studies of concentrations of serotonin reuptake inhibitors (SRIs) versus therapeutic efficacy have yielded inconsistent results. Even if the relationships between the individual's serotonergic system and the clinical symptoms of obsessive-compulsive disorder (OCD) are poorly understood, the SRIs are consistently effective in OCD. However, studies on SRI concentrations in OCD treatment are rare.

Objectives/aims: To identify possible links between paroxetine concentrations and anti-obsessive response.

Methods: In a randomised, double-blind trial, comparing clomipramine, paroxetine and placebo in OCD treatment, serum paroxetine levels were measured after 1 week and after 4 weeks of treatment in 18 patients. Anti-obsessive response was assessed with Yale-Brown obsessive compulsive scale (Y-BOCS) and patients’ global evaluation (PGE), after 12 weeks of treatment.

Results: Serum paroxetine concentrations after 4 weeks suggested a therapeutic interval between 50 and 240 nmol/L (13–63 ng/mL). The mean Y-BOCS decrease was 54% inside versus 7% outside this interval (t = 3.96; P = 0.0011).

Conclusions: Paroxetine levels seemingly predicted clinical outcome. Studies with a greater number of patients are necessary in order to confirm this finding and to discern whether it is useful in clinical practice.

sted, utgiver, år, opplag, sider
Elsevier, 2017. Vol. 41, nr Suppl., s. S322-S322
HSV kategori
Forskningsprogram
Psykiatri
Identifikatorer
URN: urn:nbn:se:oru:diva-58970DOI: 10.1016/j.eurpsy.2017.02.245ISI: 000404952400060OAI: oai:DiVA.org:oru-58970DiVA, id: diva2:1129535
Tilgjengelig fra: 2017-08-04 Laget: 2017-08-04 Sist oppdatert: 2018-08-01bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekst

Person

Humble, Mats B.

Søk i DiVA

Av forfatter/redaktør
Humble, Mats B.
Av organisasjonen
I samme tidsskrift
European psychiatry

Søk utenfor DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric

doi
urn-nbn
Totalt: 395 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf